skip navigation

Skip Nav

HIV/AIDS Clinical Trials

Clinical Trial Search Results

244 studies were found about ( raltegravir OR Isentress )

A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV

Condition: Human Immunodeficiency Virus (HIV); HIV Associated Neurocognitive Disorders (HAND)

NCT ID: NCT01448486

A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance

Condition: HIV; HIV Infections

NCT ID: NCT01042652

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients

Condition: HIV-1 Infection; HIV Infections

NCT ID: NCT01000818

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

Condition: HIV; Hyperlipidemia; Hypertriglyceridemia; HIV Infections

NCT ID: NCT00887653

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Condition: HIV Infections; Acquired Immune Deficiency Syndrome

NCT ID: NCT01173510

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

Condition: HIV Infection; HIV Infections

NCT ID: NCT00943540

Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1

Condition: HIV-1; HIV Infections

NCT ID: NCT00807443

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

Condition: HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT00105157

Raltegravir Activity In Lymphoid Tissues

Condition: HIV Infection; HIV Infections

NCT ID: NCT00863668

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men

Condition: HIV Prevention; HIV Infections

NCT ID: NCT01087840

A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)

Condition: HIV-1 Infection

NCT ID: NCT01213316

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Condition: HIV Infections

NCT ID: NCT00808002

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

Condition: HIV Infection; Inflammation; Cardiovascular Disease; HIV Infections

NCT ID: NCT00843713

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

Condition: HIV Infections

NCT ID: NCT01048671

HIV Persistence and Viral Reservoirs

Condition: HIV; HIV Infections

NCT ID: NCT01025427

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

Condition: HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT00100048

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

Condition: Hepatitis C, Chronic; HIV Infection

NCT ID: NCT01147107

Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan

Condition: HIV Infections

NCT ID: NCT01467349

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Condition: Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections

NCT ID: NCT00814879

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily

Condition: HIV-1 Infection; HIV Infections

NCT ID: NCT01121809

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

Condition: Human Immunodeficiency Virus

NCT ID: NCT00781287

Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load

Condition: HIV Infections

NCT ID: NCT00454337

Raltegravir in the Swiss HIV Cohort Study

Condition: HIV Infection

NCT ID: NCT00904644

Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection

Condition: HIV; Pregnancy

NCT ID: NCT01854762

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

Condition: HIV Infections

NCT ID: NCT00614458

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

Condition: HIV Infections

NCT ID: NCT00654147

A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection

Condition: Infection; HIV

NCT ID: NCT01697046

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Condition: HIV Infection; Osteopenia

NCT ID: NCT01902186

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression

Condition: HIV Infections

NCT ID: NCT00554398

R5 Integrase Study in HIV-1 Naive Patients

Condition: HIV Infections

NCT ID: NCT01204905

Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV

Condition: HIV Infections

NCT ID: NCT00995241

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection

Condition: HIV Infections

NCT ID: NCT01780831

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain

Condition: HIV Infections

NCT ID: NCT00685191

Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients

Condition: HIV Infections

NCT ID: NCT01190124

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

Condition: HIV Infections

NCT ID: NCT00460382

Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women

Condition: HIV Infections

NCT ID: NCT00745368

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01533259

Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.

Condition: HIV Integrase, HIV Protease.

NCT ID: NCT01258374

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

Condition: HIV Infections

NCT ID: NCT00752037

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Condition: HIV Infections

NCT ID: NCT00667433

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Condition: HIV Infections; HCV Infections

NCT ID: NCT01288417

Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression

Condition: HIV Infection

NCT ID: NCT00787774

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Condition: HIV Infections

NCT ID: NCT00594646

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

Condition: HIV Infections

NCT ID: NCT00672932

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product

Condition: HIV Infections

NCT ID: NCT00773708

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Condition: HIV Infections; Tuberculosis

NCT ID: NCT00822315

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

Condition: HIV Infections

NCT ID: NCT00740064

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

Condition: HIV Infections

NCT ID: NCT00884793

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

Condition: HIV Infections

NCT ID: NCT00718536

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

Condition: HIV Infections

NCT ID: NCT02097108

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response

Condition: HIV Infections

NCT ID: NCT00772590

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Condition: HIV Infections; Hepatitis C

NCT ID: NCT01105611

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

Condition: HIV Infection; HIV Infections

NCT ID: NCT00858962

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00762892

Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery

Condition: HIV Infections

NCT ID: NCT00562510

New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00908544

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

Condition: HBV Coinfection; HIV Infections

NCT ID: NCT01318096

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

Condition: HIV; Osteopenia; Osteoporosis; HIV Infections

NCT ID: NCT00939874

Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia

Condition: HIV Infection; Hemophilia A

NCT ID: NCT00797381

Transplantation and the Use of Raltegravir in HIV-Infected Patients

Condition: HIV Positive; Organ Transplant Recipient; Active Wait Listing for Organ Transplant

NCT ID: NCT01793467

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Condition: HIV Infections

NCT ID: NCT01066962

Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women

Condition: HIV Infections

NCT ID: NCT00961272

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)

Condition: HIV Infection

NCT ID: NCT01576731

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (0518-295)

Condition: HIV Infections

NCT ID: NCT01930045

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

Condition: HIV-1 Infection

NCT ID: NCT00709397

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

Condition: HIV Infections; Treatment Experienced

NCT ID: NCT00976404

Renal Transplantation and Raltegravir in HIV-Infected Patients

Condition: HIV-1 Infection; Chronic Renal Insufficiency

NCT ID: NCT01453192

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

Condition: HIV-1 Infections

NCT ID: NCT00984152

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Condition: HIV Infections

NCT ID: NCT00525733

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

Condition: HIV-1 Infection

NCT ID: NCT01480713

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Condition: HIV-2 Infection

NCT ID: NCT01605890

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

Condition: HIV Infection

NCT ID: NCT00641641

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients

Condition: Chronic Infection With HIV

NCT ID: NCT01829802

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

Condition: HIV Infections

NCT ID: NCT00529243

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

Condition: HIV Infections

NCT ID: NCT01047995

Safety and Effectiveness of Raltegravir in HIV-Infected Children and Adolescents

Condition: HIV Infections

NCT ID: NCT00485264

A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)

Condition: HIV Infections

NCT ID: NCT01622673

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Condition: HIV Infections

NCT ID: NCT00632970

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV

Condition: HIV Infection; Tuberculosis

NCT ID: NCT01601626

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

Condition: HIV Infection

NCT ID: NCT00443703

Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients

Condition: HIV Infections; Tuberculosis

NCT ID: NCT01059422

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

Condition: HIV Infections

NCT ID: NCT00369941

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With HIV-1

Condition: HIV Infection

NCT ID: NCT01717287

Switching From PI to RALtegravir in HIV Stable Patients

Condition: HIV Infections

NCT ID: NCT00528892

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

Condition: HIV Infections

NCT ID: NCT00293267

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019 EXT2)

Condition: HIV Infections

NCT ID: NCT00293254

Evaluating the Safety, Tolerance, Drug Interactions, and Effective Dosing of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in ART-Naive Children Infected With HIV and TB

Condition: HIV Infections; Tuberculosis

NCT ID: NCT01751568

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Condition: HIV

NCT ID: NCT01214759

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Condition: HIV Infections

NCT ID: NCT02116660

Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria

Condition: HIV Infections; Proteinuria

NCT ID: NCT01044771

CHANGES IN LIVER STEATOSIS AFTER SWITCHING TO RALTEGRAVIR IN HIV/HCV COINFECTION

Condition: HCV Coinfection; HIV Infection

NCT ID: NCT01900015

Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis

Condition: Human Immunodeficiency Virus; Hepatitis C

NCT ID: NCT01289951

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)

Condition: HIV Infection

NCT ID: NCT00443729

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Condition: Human Immunodeficiency Virus

NCT ID: NCT01814722

Raltegravir Switch for Toxicity or Adverse Events

Condition: HIV/AIDS; Antiretroviral Therapy; HIV Infections

NCT ID: NCT00958100

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Condition: HIV-1 Infections

NCT ID: NCT01033760

Isentress Re-examination Study (MK-0518-115)

Condition: HIV Infection; HIV Infections

NCT ID: NCT01042808

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

Condition: HIV-1 Infections

NCT ID: NCT00830804

Raltegravir Therapy for Women With HIV and Fat Accumulation

Condition: HIV Infections; Lipodystrophy

NCT ID: NCT00656175

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

Condition: HIV-1 Infection

NCT ID: NCT01989910

Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation

Condition: HIV-1

NCT ID: NCT01168167

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT01384734

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Condition: HIV

NCT ID: NCT01293123

Raltegravir Intensification in HIV-infected Patients

Condition: HIV Infections

NCT ID: NCT00631449

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients

Condition: HIV

NCT ID: NCT01291459

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

Condition: HIV; AIDS

NCT ID: NCT00774683

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Condition: HIV; Hepatitis C; Liver Fibrosis

NCT ID: NCT01231685

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Condition: HIV Infections

NCT ID: NCT00660972

Pilot Study of the Impact of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Undetectable Plasma Virus

Condition: HIV Infections

NCT ID: NCT00618371

Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

Condition: HIV Infection

NCT ID: NCT00707733

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Condition: HIV

NCT ID: NCT01343225

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Condition: HIV

NCT ID: NCT00931801

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

Condition: HIV Infection

NCT ID: NCT00708162

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

Condition: HIV Infections

NCT ID: NCT01114425

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

Condition: HIV

NCT ID: NCT01201239

Europe-Africa Research Network for Evaluation of Second-line Therapy

Condition: Human Immunodeficiency Virus; HIV

NCT ID: NCT00988039

Integrase Inhibitor (MK-0518) Viral Decay

Condition: HIV Infections

NCT ID: NCT00520897

Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients

Condition: Cardiovascular Disease; HIV Infections

NCT ID: NCT01066065

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT00950859

Measurement of Plasma and Intracellular Concentrations of Raltegravir

Condition: HIV

NCT ID: NCT01214486

A Prospective, Open-label Trial of Two Abacavir/Lamivudine Based Regimen (ABC/3TC + Darunavir/Ritonavir or ABC/3TC + Raltegravir) in Late Presenter naïve Patients (With CD4 Count <200 Cells/µL - Advanced HIV Disease)

Condition: HIV Infection

NCT ID: NCT01900106

Raltegravir and Atazanavir Dosing Strategy Study

Condition: HIV Infection

NCT ID: NCT00874523

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

Condition: HIV Infection; Adverse Drug Reaction; Quality of Life

NCT ID: NCT01679964

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Condition: HIV Infection; Liver Failure; Evidence of Liver Transplantation

NCT ID: NCT01022476

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Condition: HIV Infection; Hepatitis C

NCT ID: NCT01285050

Kaletra-isentress Treatment Evaluation

Condition: HIV Infections

NCT ID: NCT00700115

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

Condition: HIV; HIV-associated Neurocognitive Disorder; Neurotoxicity

NCT ID: NCT01978743

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients

Condition: HIV Infections

NCT ID: NCT00935480

RAltegravir Switch STudy: Effects on Endothelial Recovery

Condition: HIV Infection; Endothelial Dysfunction

NCT ID: NCT01453933

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Condition: HIV-1 Adults Patients; AIDS; Triple Class Failure

NCT ID: NCT01013987

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)(COMPLETED)

Condition: Human Immunodeficiency Virus

NCT ID: NCT00764946

Intense Acute Infection Study

Condition: Acute HIV Infection

NCT ID: NCT01154673

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection

Condition: Acute HIV Infection

NCT ID: NCT00734344

GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance

Condition: HIV-1 Infected Patients; Fold-change Resistance; Resistance Mutations

NCT ID: NCT01381328

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

Condition: HIV Infections

NCT ID: NCT00515827

Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects

Condition: HIV

NCT ID: NCT00765271

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

Condition: HIV

NCT ID: NCT00738569

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Condition: HIV; Hepatitis C

NCT ID: NCT01225705

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

Condition: HIV Infections

NCT ID: NCT00377065

Raltegravir Insulin Sensitivity Study

Condition: HIV Infections

NCT ID: NCT00531999

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

Condition: Human Immunodeficiency Virus; Lipohypertrophy

NCT ID: NCT01420523

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01199731

Evaluating the Response to Three Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

Condition: HIV Infections

NCT ID: NCT01618305

Effect of Antacids on the Pharmacokinetics of Raltegravir

Condition: HIV Infections

NCT ID: NCT00944307

Pharmacokinetics of Low Dose Raltegravir

Condition: HIV Infections

NCT ID: NCT01159132

Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum

Condition: HIV Infections

NCT ID: NCT00689910

Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infection

NCT ID: NCT00811954

Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz

Condition: Sleep Disorders; HIV Infections

NCT ID: NCT00944957

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

Condition: HIV Infections

NCT ID: NCT01288755

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

Condition: HIV Infections

NCT ID: NCT00751530

The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)

Condition: HIV Infections; Depression; Mild Cognitive Impairment

NCT ID: NCT01246804

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Condition: Infection, Human Immunodeficiency Virus I

NCT ID: NCT01227824

Simplification From Protease Inhibitors to Raltegravir

Condition: HIV Infections

NCT ID: NCT00941083

Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid

Condition: HIV Infections

NCT ID: NCT00729924

CCRC: A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy

Condition: HIV Infections; AIDS

NCT ID: NCT00661960

Pilot Study of Raltegravir Lipodystrophy IISP

Condition: HIV Infection

NCT ID: NCT01164605

Switch to Maraviroc + Raltegravir

Condition: HIV

NCT ID: NCT01896921

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

Condition: HIV Infections

NCT ID: NCT01294761

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Condition: HIV Infections

NCT ID: NCT00752856

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

Condition: HIV Infections

NCT ID: NCT00677300

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Condition: HIV

NCT ID: NCT00745823

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

Condition: HIV

NCT ID: NCT01245101

DDI HV (ATV - Merck)

Condition: HIV Infections

NCT ID: NCT00518297

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Condition: Human Immunodeficiency Virus Infection

NCT ID: NCT00711009

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

Condition: HIV Infections

NCT ID: NCT00870363

Raltegravir Treatment in Patients Failing Highly Active Antiretroviral Therapy (HAART) in Denmark

Condition: HIV Infections

NCT ID: NCT01061957

Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

Condition: HIV

NCT ID: NCT01597180

Cerebrospinal Fluid (CSF) Raltegravir Substudy

Condition: HIV Infections

NCT ID: NCT00718029

Evaluation of Raltegravir During the Third Trimester of Pregnancy

Condition: HIV-1 Infection; PREGNANCY

NCT ID: NCT02099474

Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

Condition: AIDS/HIV PROBLEM

NCT ID: NCT01844310

Observational Data Analysis in EuroSIDA (0518-058)

Condition: HIV-1 Infections

NCT ID: NCT01078233

Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network (MK-0518-268)

Condition: HIV-1 Infections

NCT ID: NCT01078246

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Condition: HIV

NCT ID: NCT01270802

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

Condition: HIV Infections

NCT ID: NCT00488059

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01231516

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Condition: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic

NCT ID: NCT00782301

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

Condition: Human Immunodeficiency Virus

NCT ID: NCT01825031

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Condition: Hepatitis C; HIV

NCT ID: NCT01565889

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)

Condition: HIV Infections

NCT ID: NCT00665717

Atripla to Raltegravir Switch Study

Condition: HIV Infection

NCT ID: NCT01195467

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Condition: HIV Infections

NCT ID: NCT01101893

RAL-eve Study: Raltegravir Substitution Study

Condition: HIV Infections

NCT ID: NCT00523237

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

Condition: HIV Infections

NCT ID: NCT00751153

The Raltegravir and Ribavirin Pharmacokinetics (PK) Study

Condition: HIV Infections

NCT ID: NCT00982553

Pharmacokinetic Study on Raltegravir and Lamotrigine

Condition: HIV Infection

NCT ID: NCT00618241

Impact of Raltegravir on the Viral Reservoirs

Condition: HIV Infection

NCT ID: NCT01249560

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

Condition: HIV Infections

NCT ID: NCT00931463

The Raltegravir 60+ Study

Condition: HIV

NCT ID: NCT01335620

Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants

Condition: HIV Infections

NCT ID: NCT01828073

Immune Responses in Patients Treated With Raltegravir

Condition: HIV Infections

NCT ID: NCT00785967

Phase IIB Pilot of Atazanavir + Raltegravir

Condition: HIV

NCT ID: NCT00768989

Sex, Aging and Antiretroviral Pharmacokinetics

Condition: HIV Infections

NCT ID: NCT00666055

Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections

NCT ID: NCT00977756

Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

Condition: HIV-1

NCT ID: NCT01529749

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

Condition: Women's Health; HIV Infection; Genital Diseases, Female

NCT ID: NCT01456962

Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

Condition: HIV

NCT ID: NCT01712425

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers

Condition: Human Immunodeficiency Virus

NCT ID: NCT01027182

A Key Link for Transmission Prevention

Condition: HIV

NCT ID: NCT01450189

Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study

Condition: HIV, Combination Therapy

NCT ID: NCT01332227

Study of Options for Second-Line Effective Combination Therapy (SELECT)

Condition: HIV-1 Infection

NCT ID: NCT01352715

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.

Condition: HIV; Cardiovascular Disease

NCT ID: NCT01258439

Third Line Antiretroviral Threatment Optimization in Sub-Saharan Africa

Condition: HIV Infection

NCT ID: NCT02025868

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Condition: HIV-1 Infection

NCT ID: NCT01641367

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients

Condition: HIV-1 Infection

NCT ID: NCT01019551

Optimizing Treatment for Treatment-Experienced, HIV-infected People

Condition: HIV Infections

NCT ID: NCT00537394

Post-Exposure Prophylaxis in Health Care Workers

Condition: Human Immunodeficiency Virus

NCT ID: NCT01234116

Genotypic Resistant HIV Strains in Taiwan

Condition: HIV-1; HIV Infections

NCT ID: NCT00954863

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.

Condition: HIV; Hypercholesterolaemia

NCT ID: NCT01779687

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).

Condition: HIV; Depression

NCT ID: NCT01978782

Levels of Raltegravir in the Female Genital Tissue

Condition: HIV

NCT ID: NCT01327482

Raltegravir and Ezetimibe PK Study

Condition: HIV

NCT ID: NCT00772551

The Effect of Intermittent Rifampicin on Raltegravir

Condition: HIV; Tuberculosis

NCT ID: NCT01424826

The Effect of Antacids and Multivitamins on Raltegravir

Condition: HIV

NCT ID: NCT01784302

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01568892

A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers

Condition: HIV

NCT ID: NCT01841593

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00851799

The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters

Condition: HIV; Pregnancy

NCT ID: NCT01251601

Bone and Body Comp: A Sub Study of the SECOND-LINE Study

Condition: HIV

NCT ID: NCT01513122

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Condition: HIV Infections

NCT ID: NCT00440271

Intensive Viral Dynamics Substudy of A5248

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00852618

Impact of a Raltegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients

Condition: Severely Immunocompromised HIV Patients

NCT ID: NCT01837277

Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy

Condition: HIV Infections

NCT ID: NCT00559416

To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients

Condition: Evaluated; Non B Subtype; Naive Patients

NCT ID: NCT01162538

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01328041

Evaluating the Safety and Efficacy of Single-Dose Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

Condition: HIV Infections

NCT ID: NCT01933594

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

Condition: HIV-1 Infection

NCT ID: NCT01966822

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Condition: HIV Infections

NCT ID: NCT01026727

Kaletra in Combination With Antiretroviral Agents

Condition: Human Immunodeficiency Virus

NCT ID: NCT01076179

EARNEST Rifabutin Pharmacokinetics (PK) Substudy

Condition: HIV; Tuberculosis

NCT ID: NCT01663168

Preliminary Study of Zidovudine Addition for HIV-associated Neurocognitive Disorder

Condition: HIV Associated Neurocognitive Disorder

NCT ID: NCT01966094

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

Condition: HIV; AIDS; Lopinavir; Treatment Failure

NCT ID: NCT01189695

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01458132

Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects

Condition: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections

NCT ID: NCT02016924

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Condition: This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy.

NCT ID: NCT01225406

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Condition: Hepatitis C, Chronic; HIV Infection

NCT ID: NCT01332955

Antiretroviral Therapy for Acute HIV Infection

Condition: Acute HIV Infection

NCT ID: NCT00796263

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

HIV Resistance and Treatment Strategies

Condition: HIV Infections

NCT ID: NCT00581802

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

Condition: Human Immunodeficiency Virus; Hepatitis B, Chronic; Hepatitis C, Chronic

NCT ID: NCT01908660

Concentrations of Raltegravir in the Semen of HIV-Infected Men

Condition: Raltegravir Concentrations in Semen

NCT ID: NCT01045265

Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.

Condition: Pharmacokinetics

NCT ID: NCT00746499

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

Condition: Virologic Response

NCT ID: NCT00749580

Telaprevir Open-Label Study in Co-Infected Patients

Condition: Hepatitis C, Chronic

NCT ID: NCT01500616

Concentrations of Maraviroc in the Semen of HIV-Infected Men

Condition: Maraviroc Concentrations in Semen

NCT ID: NCT01009034